These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8797053)

  • 1. Familial type V hyperlipoproteinemia with hyper-remnant-like particle-cholesterol accompanied with apolipoprotein E3/E4 phenotype.
    Nagai T; Tomizawa T; Saito T; Nakano T; Nakajima K; Mori M
    Intern Med; 1996 May; 35(5):388-91. PubMed ID: 8797053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia.
    Ghiselli G; Schaefer EJ; Zech LA; Gregg RE; Brewer HB
    J Clin Invest; 1982 Aug; 70(2):474-7. PubMed ID: 7096573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E phenotype frequency in type II diabetic patients with different forms of hyperlipoproteinemia.
    Parhofer KG; Richter WO; Schwandt P
    Horm Metab Res; 1990 Nov; 22(11):589-94. PubMed ID: 2272605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of moderate hypertriglyceridemia with apolipoprotein E phenotype E4/3.
    Kojima S; Homma Y; Sakane H; Kobayashi T; Ozawa H; Okajima Y
    Tokai J Exp Clin Med; 1996 Dec; 21(4-6):165-9. PubMed ID: 9300976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment.
    Janus ED; Grant S; Lintott CJ; Wardell MR
    Atherosclerosis; 1985 Nov; 57(2-3):249-66. PubMed ID: 3866582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes.
    Saito M; Eto M; Kaku K
    Metabolism; 2002 Aug; 51(8):964-9. PubMed ID: 12145767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients.
    Yamada M
    J Atheroscler Thromb; 1997; 4(1):40-4. PubMed ID: 9583353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of apolipoproteins E and C in type V hyperlipoproteinemia.
    Kuusi T; Taskinen MR; Solakivi T; Kauppinen-Mäkelin R
    J Lipid Res; 1988 Mar; 29(3):293-8. PubMed ID: 3379342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chylomicronaemia in multiple myeloma.
    Aviram M; Carter A; Brook JG; Tatarsky I
    Scand J Haematol; 1985 May; 34(5):436-41. PubMed ID: 4012223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interruption of long-term lipid-lowering treatment with bezafibrate in hypertriglyceridaemic patients. Effects on lipoprotein composition, lipase activities and the plasma lipid fatty acid spectrum.
    Vessby B; Lithell H
    Atherosclerosis; 1990 May; 82(1-2):137-43. PubMed ID: 2360915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
    Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between variant apolipoproteins C-II and E that affects plasma lipoprotein concentrations.
    Hegele RA; Breckenridge WC; Cox DW; Maguire GF; Little JA; Connelly PW
    Arterioscler Thromb; 1991; 11(5):1303-9. PubMed ID: 1911716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.
    Rubinstein A; Gibson JC; Paterniti JR; Kakis G; Little A; Ginsberg HN; Brown WV
    J Clin Invest; 1985 Feb; 75(2):710-21. PubMed ID: 3973025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
    Oscarsson J; Hurt-Camejo E
    Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E.
    Weintraub MS; Eisenberg S; Breslow JL
    J Clin Invest; 1987 Dec; 80(6):1571-7. PubMed ID: 3479440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal in vivo metabolism of apolipoprotein E4 in humans.
    Gregg RE; Zech LA; Schaefer EJ; Stark D; Wilson D; Brewer HB
    J Clin Invest; 1986 Sep; 78(3):815-21. PubMed ID: 3745440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remnant-like particles (RLP) from NIDDM patients with apolipoprotein E3/3 phenotype stimulate cholesteryl ester synthesis in human monocyte-derived macrophages.
    Saito M; Eto M; Okada M; Iwashima Y; Makino I
    Artery; 1996; 22(3):155-63. PubMed ID: 8893973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype.
    Brenninkmeijer BJ; Stuyt PM; Demacker PN; Stalenhoef AF; van 't Laar A
    J Lipid Res; 1987 Apr; 28(4):361-70. PubMed ID: 3585171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.